By the Top Tier Newswire AI Desk · September 29, 2026 at 3:11 PM ET · reviewed against 3 wire stories
ABCELLERA BIOLOGICS (ABCL) is up +6.65% in the latest session. Our newswire has captured 3 stories on ABCL across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ABCL stock rose 6.65% to $14.85 on Tuesday, driven primarily by JPMorgan initiating coverage with an Overweight rating. The move followed a strong opening gap and elevated call volume, reflecting renewed investor interest in the biotech firm. The stock’s rally came amid recent positive developments, including insider buying and a presentation of clinical data at an upcoming conference.
What Happened
JPMorgan initiated coverage of AbCellera Biologics with an Overweight rating and a $17 price target, according to Benzinga. This action came alongside a broader market reaction that saw the stock open with a 2.9% gap up at $14.32. The session high reached $14.91 at 2:05 PM ET, with the stock trading near that level at the close. Goldman Sachs also reinstated a Neutral rating with a $13 price target, but the JPMorgan upgrade appeared to have the stronger immediate impact. Meanwhile, AbCellera is scheduled to present Phase 2 data on ABCL635 at the IMS 20th World Congress on Menopause, adding to the stock’s near-term catalysts.
What The Data Shows
The stock has gained 15.3% over the past eight sessions, rising from $12.63 to $14.56. Trading volume for the session reached 5.8 million shares, or 0.8 times the 3-month average, with call volume above normal and directionally bullish. Insiders have been active buyers, with four transactions totaling $1.5 million in the last 90 days. The stock closed at a fresh 52-week high on 2026-09-29, having printed six new highs and one new low that day. Despite strong revenue growth of 101.3% in the trailing twelve months, the company remains unprofitable with a net margin of -248.8% and a beta of 1.32, indicating higher volatility than the broader market.
What To Watch
Investors should monitor AbCellera’s presentation of Phase 2 data on ABCL635 at the IMS 20th World Congress on Menopause for further momentum. The stock is also approaching the upper end of its 52-week range, with more catalysts likely to emerge in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
JPMorgan initiates AbCellera stock coverage with overweight rating
JPMorgan initiates AbCellera stock coverage with overweight rating
13h agoThe FlyBULLISH 63Analyst
AbCellera initiated with an Overweight at JPMorgan
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →